Targeted maternal screening could eliminate aggressive T-cell leukemia in high-risk U.S. populations

Targeted prenatal screening for HTLV-1 could eliminate Adult T-cell leukemia/lymphoma in high-risk groups, according to new research from the University of Miami.

By: AXL Media

Published: May 2, 2026, 3:40 AM EDT

Source: Information for this report was sourced from the University of Miami Miller School of Medicine

A Hidden Viral Driver of Fatal Cancer

A landmark study from the University of Miami Miller School of Medicine has revealed that Adult T-cell leukemia/lymphoma (ATLL), a rare and often fatal malignancy, is largely preventable through proactive maternal health interventions. The research, published in JAMA Oncology, identifies human T-cell leukemia virus type 1 (HTLV-1) as the sole cause of the disease. While the virus often remains dormant for decades, it is frequently transmitted from mother to child through breastfeeding, creating a long-term reservoir for cancer development. By identifying and intercepting this transmission early, physicians believe they can eliminate the lifetime risk of ATLL for thousands of high-risk individuals.

Disproportionate Impact on Caribbean Immigrants

The study, led by Dr. Paulo Pinheiro, utilized nearly twenty years of cancer registry data from all 50 U.S. states to map the incidence of ATLL across various demographics. The findings indicate a stark geographical and ancestral pattern, with incidence rates among non-Hispanic Caribbean-born residents being more than 30 times higher than those born in the U.S. or Canada. Florida and New York, which host the largest Caribbean-born populations in the country, accounted for nearly half of all recorded cases. This data reframes ATLL not as a random rarity, but as a predictable public health challenge concentrated in specific, identifiable communities.

The Diagnostic Blind Spot and Misclassification

One of the most troubling aspects of the research is the evidence that the true burden of ATLL is significantly undercounted due to medical misclassification. Because HTLV-1 testing is not a routine part of oncology workups in the U.S., many ATLL cases are incorrectly coded as "peripheral T-cell lymphoma not otherwise specified." Sensitivity analyses conducted by the team suggest that the actual incidence of the disease among Caribbean-born individuals may be nearly double what is officially reported. This diagnostic gap not only obscures the scale of the problem but also prevents patients from receiving specialized treatments tailored to the retroviral nature of the cancer.